record_id,policy_type,policy_op,policy_specific,policy_specific_new,outcomes_yn,out_op,out_specific,out_code,out_code_name,impact_var,other_outcome,impact
Abadie_2018,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Abadie_2018,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Abadie_2018,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Abadie_2018,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Abouk_2019,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Abouk_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Abramson_2009,1_legal,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Abramson_2009,1_legal,policy_criminal,9090_Availability of harm reduction in corrections facilities,9090_Availability of harm reduction in corrections facilities,0,NA,NA,NA,NA,NA,NA,NA
Abramson_2009,1_legal,policy_theme,9090_International human rights treaties,9090_International human rights treaties,0,NA,NA,NA,NA,NA,NA,NA
Abramson_2009,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Abramson_2009,4_government policy,policy_criminal,9090_Availability of harm reduction in corrections facilities,9090_Availability of harm reduction in corrections facilities,0,NA,NA,NA,NA,NA,NA,NA
Abramson_2009,4_government policy,policy_theme,9090_International human rights treaties,9090_International human rights treaties,0,NA,NA,NA,NA,NA,NA,NA
Accurso_2016,7_programs,policy_theme,9090_Private insurance coverage changes,9090_Private insurance coverage changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,NA
Accurso_2016,7_programs,policy_theme,9090_Private insurance coverage changes,9090_Private insurance coverage changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Aguiar_2016,2_legislations,policy_criminal,9090_Parenting Sentencing Alternative,9090_Parenting Sentencing Alternative,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Ahammer_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Ahammer_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Aitken_2002,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,4_detrimental
Aitken_2002,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Aitken_2002,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,4_detrimental
Aitken_2002,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Al Achkar_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Alburaih_2018,7_programs,policy_theme,9090_Standardised pain contract,9090_Standardised pain contract,1,outcome_type,9090_ED attendance,999,other 1,impact_other,9090_ED attendance,2_decrease
Alburaih_2018,7_programs,policy_theme,9090_Standardised pain contract,9090_Standardised pain contract,1,outcome_type,9090_ED attendance,999,other 1,impact_other,9090_ED attendance,3_beneficial
Aletraris_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Aletraris_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Aletraris_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcomes_treatment,1_access,1,access,impact_access,NA,0_no change
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,4_detrimental
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,4_detrimental
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcome_type,9090_3_effect of incarceration of mother on child,999,other 1,impact_other,9090_3_effect of incarceration of mother on child,1_increase
Alexander_2014,2_legislations,policy_criminal,9090_Punitive charges for drug use while pregnant (specifically assault on fetus),9090_pregnancy_related_drug_charges,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,0_no change
Alexandridis_2018,8_strategies,policy_harm,9090_naloxone distribution,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Alexandridis_2018,8_strategies,policy_harm,9090_naloxone distribution,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Alexandridis_2018,8_strategies,policy_theme,9090_Education providers,9090_Education providers,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Alexandridis_2018,8_strategies,policy_theme,9090_Education providers,9090_Education providers,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Alexandridis_2018,8_strategies,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Alexandridis_2018,8_strategies,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Alexandridis_2019,2_legislations,policy_harm,9090_naloxone policies,9090_naloxone_access_policies,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_harm,9090_naloxone policies,9090_naloxone_access_policies,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_social,9090_Support programs,9090_Support programs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_social,9090_Support programs,9090_Support programs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_social,9090_2_Education programs,9090_2_Education programs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_social,9090_2_Education programs,9090_2_Education programs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,2_legislations,policy_prescription,9090_diversion control,9090_diversion,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,2_legislations,policy_prescription,9090_diversion control,9090_diversion,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_harm,9090_naloxone policies,9090_naloxone_access_policies,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_harm,9090_naloxone policies,9090_naloxone_access_policies,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_social,9090_Support programs,9090_Support programs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_social,9090_Support programs,9090_Support programs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_social,9090_2_Education programs,9090_2_Education programs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_social,9090_2_Education programs,9090_2_Education programs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Alexandridis_2019,7_programs,policy_prescription,9090_diversion control,9090_diversion,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Alexandridis_2019,7_programs,policy_prescription,9090_diversion control,9090_diversion,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Ali_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Ali_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Ali_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Allen_2016,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_Availability of NSP available in high risk areas when 1000 foot rule in place (distance from school),999,other 1,impact_other,9090_Availability of NSP available in high risk areas when 1000 foot rule in place (distance from school),2_decrease
Allen_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_Stigma,999,other 1,impact_other,9090_Stigma,4_detrimental
Allen_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_Stigma,999,other 1,impact_other,9090_Stigma,999_unclear
Almarsdottir_2000,2_legislations,policy_legislative,9090_liberalizing community pharmacy ownership,9090_liberalizing community pharmacy ownership,1,outcome_otc,2_non-prescription drug use,2,non-prescription drug use,impact_otc,NA,0_no change
Alpert_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Alpert_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Alpert_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Alsirafy_2011,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,9090_Pain treatment for advanced cancer patients,999,other 1,impact_other,9090_Pain treatment for advanced cancer patients,2_decrease
Alsirafy_2011,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,9090_Pain treatment for advanced cancer patients,999,other 1,impact_other,9090_Pain treatment for advanced cancer patients,4_detrimental
Anders_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Anders_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Anders_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Anders_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Anders_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Anders_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Andraka-Christou_2016,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2016,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2016,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2016a,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2016a,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,2_legislations,policy_social,9090_mandated counseling,9090_mandated counseling,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,7_programs,policy_social,9090_mandated counseling,9090_mandated counseling,0,NA,NA,NA,NA,NA,NA,NA
Andraka-Christou_2017,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,3_beneficial
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Andresen_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Andrews_2014,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_Acceptance of Medicaid by substance abuse treatment providers,999,other 1,impact_other,9090_Acceptance of Medicaid by substance abuse treatment providers,3_beneficial
Andrews_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Acceptance of medicaid for SUT,999,other 1,impact_other,9090_Acceptance of medicaid for SUT,NA
Andrews_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,4_detrimental
Andrews_2019_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Andrews_2019_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Angelotta_2016,1_legal,policy_criminal,9090_Court referral for substance use treatment,9090_Court referral for substance use treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Angelotta_2016,1_legal,policy_legislative,9090_Prenatal child abuse laws for women who use illicit drugs during pregnancy,9090_pregnancy_related_drug_charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Angelotta_2016,2_legislations,policy_criminal,9090_Court referral for substance use treatment,9090_Court referral for substance use treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Angelotta_2016,2_legislations,policy_legislative,9090_Prenatal child abuse laws for women who use illicit drugs during pregnancy,9090_pregnancy_related_drug_charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Angelotta_2017,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Angelotta_2017,1_legal,policy_criminal,9090_Substance use while pregnant,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Anglin_2013,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Anglin_2013_2,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Arredondo_2018,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_Arrests for possession or crime,999,other 1,impact_other,9090_Arrests for possession or crime,0_no change
Arredondo_2018,4_government policy,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,9090_Arrests for possession or crime,999,other 1,impact_other,9090_Arrests for possession or crime,0_no change
Asher_2013,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Engagement with treatment,999,other 1,impact_other,9090_Engagement with treatment,999_unclear
Atkins_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Aubrun_2007,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Auerhahn_2004,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_Incarceration rates,999,other 1,impact_other,9090_Incarceration rates,999_unclear
Ayres_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Ayres_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Azrin_2007,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,0_no change
Azrin_2007,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Azrin_2007,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,0_no change
Azzone_2011,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Azzone_2011,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Azzone_2011,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,1_increase
Bachhuber_2014,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Bachhuber_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Bachhuber_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bachhuber_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Bachhuber_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Bachhuber_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Baicker_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Baicker_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,3_beneficial
Bammer_2000,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Bammer_2000,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Bao_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,2_legislations,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,2_legislations,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,2_legislations,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,3_regulation,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,3_regulation,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,3_regulation,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,4_government policy,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,4_government policy,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,4_government policy,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,5_guidelines,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,5_guidelines,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,5_guidelines,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,7_programs,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,7_programs,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,7_programs,policy_theme,9090_Data sharing program,9090_Data sharing program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bao_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bao_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Bao_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Barber_2017,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Barnes_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Barnett_2018,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Barnett_2018,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Bartelson_2017,8_strategies,policy_clinical,9090_ER/LA Opioid Analgesic Risk Evaluation and Mitigation Strategy,9090_ER/LA Risk Evaluation and Mitigation Strategy,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Barthwell_2016,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Beaudoin_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,5_guidelines,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,7_programs,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,7_programs,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,7_programs,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,7_programs,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,7_programs,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,7_programs,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Beaudoin_2016,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Beaudoin_2016,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Beaudoin_2016,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Becquemont_2014,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,0_no change
Becquemont_2014,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,9090_2_impact of pain on daily activities,999,other 1,impact_other,9090_2_impact of pain on daily activities,0_no change
Becquemont_2014,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Beheshti_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,1_increase
Beheshti_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Beheshti_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_infectious,999_other 1,999,other 1,impact_infect_other,NA,1_increase
Beletsky_2008,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Ben-Joseph_2014,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Ben-Joseph_2014,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Ben-Joseph_2014,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Bernhardt_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Bernhardt_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Bernstein_2013,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Bernstein_2013,2_legislations,policy_legislative,9090_Municipal Zoning,9090_Municipal Zoning,0,NA,NA,NA,NA,NA,NA,NA
Best_2010,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Best_2010,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Best_2010,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Best_2010,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Biddulph_2011,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_law_enforce,2_police presence,2_police presence,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_law_enforce,9090_monitoring and surveillance,9090_monitoring and surveillance,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_clinical,7_compulsory_treatment,7_compulsory_treatment,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_theme,"9090_mandatory registration of drug users, who can then be tested for drugs at any time","9090_mandatory registration of drug users, who can then be tested for drugs at any time",0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,2_legislations,policy_clinical,9090_Coersive police treatment centres or labour camps,9090_Coersive police treatment centres or labour camps,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_law_enforce,2_police presence,2_police presence,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_law_enforce,9090_monitoring and surveillance,9090_monitoring and surveillance,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_clinical,7_compulsory_treatment,7_compulsory_treatment,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_theme,"9090_mandatory registration of drug users, who can then be tested for drugs at any time","9090_mandatory registration of drug users, who can then be tested for drugs at any time",0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Biddulph_2011,7_programs,policy_clinical,9090_Coersive police treatment centres or labour camps,9090_Coersive police treatment centres or labour camps,0,NA,NA,NA,NA,NA,NA,NA
Bird_2015,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Bird_2015,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Bird_2015,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Bird_2015,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,3_beneficial
Bird_2016,7_programs,policy_harm,9090_national naloxone programme,9090_national naloxone programme,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Bird_2016,7_programs,policy_harm,9090_national naloxone programme,9090_national naloxone programme,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Birk_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,1_access,1,access,impact_access,NA,2_decrease
Birk_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,1_access,1,access,impact_access,NA,999_unclear
Birk_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Birk_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Black_2019,8_strategies,policy_clinical,9090_ER/LA Risk Evaluation and Mitigation Strategy,9090_ER/LA Risk Evaluation and Mitigation Strategy,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Blanchard_2016,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2016,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2016,8_strategies,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2016,8_strategies,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Blanchard_2018,2_legislations,policy_harm,9090_naloxone program,9090_naloxone_access_policies,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Blanchard_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Blanchard_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Blanchard_2018,7_programs,policy_harm,9090_naloxone program,9090_naloxone_access_policies,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Blanchard_2018,7_programs,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Blanchard_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Hopsital readmission at 90 days post previous admission,999,other 1,impact_other,9090_Hopsital readmission at 90 days post previous admission,999_unclear
Bleyer_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Bluthenthal_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Bluthenthal_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,2_decrease
Bluthenthal_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_3_police harassment,998,other 2,impact_other_2,9090_3_police harassment,1_increase
Bluthenthal_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_2_number of syringes exchanged,999,other 1,impact_other,9090_2_number of syringes exchanged,2_decrease
Bobashev_2018,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,3_regulation,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,7_programs,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bobashev_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Bobashev_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Boehnke_2016,7_programs,policy_theme,9090_medical cannabis,9090_medical cannabis,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Boehnke_2016,7_programs,policy_theme,9090_medical cannabis,9090_medical cannabis,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Bohnert_2011,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Bohnert_2011,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,4_detrimental
Bohnert_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Borquez_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Boyer_2008,3_regulation,policy_theme,9090_Regulation of online pharmacies,9090_Regulation of online pharmacies,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Boyer_2008,3_regulation,policy_theme,9090_Regulation of online pharmacies,9090_Regulation of online pharmacies,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,999_unclear
Bradbury_2014,4_government policy,policy_harm,"9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management","9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,4_government policy,policy_harm,9090_2_Naloxone - THN,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,4_government policy,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,7_programs,policy_harm,"9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management","9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,7_programs,policy_harm,9090_2_Naloxone - THN,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,7_programs,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,8_strategies,policy_harm,"9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management","9090_pre-release (from prison) counselling on OD risks and prevention, and training in 1st aid and OD management",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,8_strategies,policy_harm,9090_2_Naloxone - THN,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,8_strategies,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Bradbury_2014a,4_government policy,policy_harm,9090_Naloxone - THN,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,4_government policy,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,7_programs,policy_harm,9090_Naloxone - THN,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,7_programs,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,8_strategies,policy_harm,9090_Naloxone - THN,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,8_strategies,policy_criminal,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,9090_This paper wasn't specifically talking about criminal justice policies; rather the whole paper is about the impact of OD and drug treatment programs for the population that is being released from prison.,0,NA,NA,NA,NA,NA,NA,NA
Bradbury_2014a,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Bradford_2016,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bradford_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Bradford_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Bradford_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Brady_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Brady_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Brands_2003,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Brands_2003,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Branham_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Branham_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,1_increase
Bravo_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Bravo_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Brighthaupt_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,999_other 1,999,other 1,impact_other,NA,3_beneficial
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Brown_2010,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,3_beneficial
Brown_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Brown_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Brown_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Brown_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Brownsberger_2004,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Brownsberger_2004,2_legislations,policy_legislative,9090_Increased penalties for dealing in school zones,9090_Increased penalties for dealing in school zones,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Bruce_2009,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Bruce_2009,5_guidelines,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Buchmueller_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Buchmueller_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Buer_2014,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Buer_2014,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Buhl_2004,2_legislations,policy_legislative,9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),1,outcomes_treatment,1_access,1,access,impact_access,NA,0_no change
Buhl_2004,2_legislations,policy_legislative,9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Buhl_2004,2_legislations,policy_legislative,9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Buhl_2004,2_legislations,policy_legislative,9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),9090_mandated responsibility for care of Problem Drug Users to govt (away from GPs and private clinics),1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Buhl_2004,2_legislations,policy_clinical,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,1,outcomes_treatment,1_access,1,access,impact_access,NA,0_no change
Buhl_2004,2_legislations,policy_clinical,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Buhl_2004,2_legislations,policy_clinical,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Buhl_2004,2_legislations,policy_clinical,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,9090_mandated responsibility for medical treatment of PDU from GP or private clinic to county/government clinic.,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Bunting_2019,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,3_regulation,policy_legislative,5_first responders,5_first responders,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,3_regulation,policy_legislative,5_first responders,5_first responders,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,3_regulation,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Bunting_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Bunting_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,NA
Bunting_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_2_injection drug use rate,999,other 1,impact_other,9090_2_injection drug use rate,NA
Burger_2017,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,4_government policy,policy_prescription,9090_Administrative barriers,9090_Administrative barriers,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,5_guidelines,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,5_guidelines,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,5_guidelines,policy_prescription,9090_Administrative barriers,9090_Administrative barriers,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,7_programs,policy_prescription,9090_Administrative barriers,9090_Administrative barriers,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,8_strategies,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,8_strategies,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,8_strategies,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,8_strategies,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Burns_2016,8_strategies,policy_prescription,9090_Administrative barriers,9090_Administrative barriers,0,NA,NA,NA,NA,NA,NA,NA
Busch_2014,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Busch_2014,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Busch_2014,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Busch_2014,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,0_no change
Butler_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Cady_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Cahill_2003,2_legislations,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,2_legislations,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,2_legislations,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,2_legislations,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cahill_2003,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cahill_2003,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cahill_2003,3_regulation,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,3_regulation,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,3_regulation,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,3_regulation,policy_legislative,"9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)","9090_Client monitoring system (ie, patient treatment list for all patients prescribed methadone)",1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cahill_2003,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cahill_2003,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Cahill_2003,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cahill_2003,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Cahill_2003,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cairns_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,9090_poison centre misuse calls,999,other 1,impact_other,9090_poison centre misuse calls,0_no change
Calsyn_2003,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Calsyn_2003,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Calsyn_2003,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,0_no change
Capoccia_2012,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Cassidy_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Cassidy_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Cassidy_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Cassidy_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Castillo-Carniglia_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Castillo-Carniglia_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Castillo-Carniglia_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Casturi_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Casturi_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
Casturi_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
CDC_nd,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_3,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_4,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_5,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_6,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,0,NA,NA,NA,NA,NA,NA,NA
CDC_nd_7,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Cerda_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Cerda_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_otc,2_non-prescription drug use,2,non-prescription drug use,impact_otc,NA,999_unclear
Chacko_2017,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Chambers_2015,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,999_unclear
Chambers_2015,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Chan_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Chang_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Chang_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Chang_2018_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Chang_2018_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Chang_2018_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Chen_2016,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Chen_2016,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Chen_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,9090_2_Post operation mortality rates,999,other 1,impact_other,9090_2_Post operation mortality rates,1_increase
Chen_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,9090_2_Post operation mortality rates,999,other 1,impact_other,9090_2_Post operation mortality rates,1_increase
Chen_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Chen_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,9090_2_Post operation mortality rates,999,other 1,impact_other,9090_2_Post operation mortality rates,1_increase
Chen_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Cherny_2010,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Cheurprakobkit_2000,4_government policy,policy_legislative,9090_Drug suppression and prevention policies,9090_Drug suppression and prevention policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Cheurprakobkit_2000,4_government policy,policy_legislative,9090_Drug suppression and prevention policies,9090_Drug suppression and prevention policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Cheurprakobkit_2000,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Cheurprakobkit_2000,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Chihuri_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Chihuri_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Chihuri_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Chilcoat_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Chiu_2018,7_programs,policy_prescription,9090_Lowering default pill counts in EMR system,9090_Lowering default pill counts in EMR system,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Chiu_2018,7_programs,policy_prescription,9090_Lowering default pill counts in EMR system,9090_Lowering default pill counts in EMR system,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Christopher_2015,2_legislations,policy_legislative,9090_substance  related civil commitment laws,9090_substance  related civil commitment laws,0,NA,NA,NA,NA,NA,NA,NA
Chu_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Chu_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Chumpitazi_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Chun_2007,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,999_unclear
Chun_2007,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Chun_2007,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,3_beneficial
Chun_2007,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Chun_2007,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,0_no change
Cicero_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Cicero_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Cicero_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Clark_2014,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,0_no change
Clark_2014,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Clark_2014,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Clark_2014,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,0_no change
Clark_2014,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Clark_2014,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Cleary_2013,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Cleary_2013_2,2_legislations,policy_prescription,9090_A variety related to restrictions on prescribing of opioids,9090_A variety related to restrictions on prescribing of opioids,0,NA,NA,NA,NA,NA,NA,NA
Cleary_2013_2,3_regulation,policy_prescription,9090_A variety related to restrictions on prescribing of opioids,9090_A variety related to restrictions on prescribing of opioids,0,NA,NA,NA,NA,NA,NA,NA
Cleary_2013_3,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cleary_2013_3,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cleary_2013_4,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cleary_2013_4,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cleary_2013_5,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cleary_2013_5,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Cochella_2011,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,999_unclear
Cochella_2011,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Cochella_2011,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Cochella_2011,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Cochran_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Cochran_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Cooper_2005,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,2_decrease
Cooper_2005_2,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,998_other 2,998,other 2,impact_dui_2,NA,1_increase
Cooper_2005_2,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,998_other 2,998,other 2,impact_dui_2,NA,2_decrease
Cooper_2005_2,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Cooper_2005_2,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Cooper_2005_2,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_illegal,998_other 2,998,other 2,impact_dui_2,NA,1_increase
Cooper_2005_2,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_illegal,998_other 2,998,other 2,impact_dui_2,NA,2_decrease
Cooper_2005_2,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Cooper_2005_2,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Coplan_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Coplan_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Coplan_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Coplan_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Coplan_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Coplan_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Corcoran_2010,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Corcoran_2010,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Corcoran_2010,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,9090_2_prescription drug sales to pharmacies,999,other 1,impact_other,9090_2_prescription drug sales to pharmacies,2_decrease
Corcoran_2010,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,9090_2_prescription drug sales to pharmacies,999,other 1,impact_other,9090_2_prescription drug sales to pharmacies,3_beneficial
Corsaro_2010,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Corsaro_2010,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Corsaro_2012,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Corsaro_2013,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Costa Storti_2009,8_strategies,policy_law_enforce,9090_supply containment policies,9090_supply containment policies,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Cotti_2014,7_programs,policy_criminal,9090_Diversion,9090_diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Courtwright_2004,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Courtwright_2004,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Cowell_2004,3_regulation,policy_criminal,9090_diversion,9090_diversion,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Cowell_2004,3_regulation,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,999_unclear
Cowell_2004,3_regulation,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,999_unclear
Cowell_2004,3_regulation,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,999_unclear
Cowell_2004,3_regulation,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,9090_3_nonviolent victimization,999,other 1,impact_other,9090_3_nonviolent victimization,2_decrease
Crabtree_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Crabtree_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Csete_2013,4_government policy,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Csete_2013,4_government policy,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Csete_2013,4_government policy,policy_criminal,1_drug courts,1_drug courts,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Csete_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Csete_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Csete_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Cunningham_2008,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,2_decrease
Danovich_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Dart_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Dart_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Dave_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Dave_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Davis_2006,3_regulation,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,9090_Number of visits to needle exchange site,999,other 1,impact_other,9090_Number of visits to needle exchange site,2_decrease
Davis_2014_1,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2014_1,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2014_2,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Davis_2014_2,3_regulation,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Davis_2014_2,4_government policy,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Davis_2015,2_legislations,policy_harm,9090_access to naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2015,3_regulation,policy_harm,9090_access to naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2015,4_government policy,policy_harm,9090_access to naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2015_2,7_programs,policy_harm,9090_naloxone administration by police,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2016,2_legislations,policy_theme,9090_CME/physician education laws,9090_CME/physician education laws,0,NA,NA,NA,NA,NA,NA,NA
Davis_2016,3_regulation,policy_theme,9090_CME/physician education laws,9090_CME/physician education laws,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,2_legislations,policy_harm,9090_prescription of naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,2_legislations,policy_harm,9090_prescription of naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,3_regulation,policy_harm,9090_prescription of naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2017,3_regulation,policy_harm,9090_prescription of naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,3_regulation,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,3_regulation,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,6_standards,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,6_standards,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,6_standards,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,6_standards,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,6_standards,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,7_programs,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,0,NA,NA,NA,NA,NA,NA,NA
Davis_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Davis_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
De Lima_2001,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,"9090_Adherence to WHO and INCB principles governing opioid access , which in turn is an indicator for opioid accessibility",999,other 1,impact_other,"9090_Adherence to WHO and INCB principles governing opioid access , which in turn is an indicator for opioid accessibility",4_detrimental
De Lima_2001,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,"9090_Adherence to WHO and INCB principles governing opioid access , which in turn is an indicator for opioid accessibility",999,other 1,impact_other,"9090_Adherence to WHO and INCB principles governing opioid access , which in turn is an indicator for opioid accessibility",4_detrimental
De Wree_2009,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Deacon_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deacon_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
DeBeck_2017,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,2_legislations,policy_law_enforce,2_police presence,2_police presence,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,3_regulation,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,3_regulation,policy_law_enforce,2_police presence,2_police presence,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,3_regulation,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeBeck_2017,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,1_increase
DeFulio_2013,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Degenhardt_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Degenhardt_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,1_increase
Degenhardt_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_3_visits to SIS to inject other opioids,998,other 2,impact_other_2,9090_3_visits to SIS to inject other opioids,2_decrease
Degenhardt_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_2_injection of Oxy-Contin,999,other 1,impact_other,9090_2_injection of Oxy-Contin,2_decrease
Deiana_2019,2_legislations,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,2_legislations,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,2_legislations,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,2_legislations,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deiana_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deiana_2019,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deiana_2019,3_regulation,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,3_regulation,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,3_regulation,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,3_regulation,policy_theme,9090_doctor shopping laws,9090_doctor shopping laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deiana_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Deiana_2019,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Deiana_2019,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Deiana_2019,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Deiana_2019,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Delcher_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Delcher_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Delcher_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Delcher_2017,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
DeSimone_2005,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
DeSimone_2005,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Dhalla_2009,8_strategies,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Dhalla_2009,8_strategies,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Dhanda_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_heroin & oat use relative to nonheroin opioid use prior to intake,999,other 1,impact_other,9090_heroin & oat use relative to nonheroin opioid use prior to intake,1_increase
Dhanda_2018,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,9090_heroin & oat use relative to nonheroin opioid use prior to intake,999,other 1,impact_other,9090_heroin & oat use relative to nonheroin opioid use prior to intake,1_increase
Dick_2015,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,1_access,1,access,impact_access,NA,3_beneficial
Dick_2015,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Dillender_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Dillender_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Dillender_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Dineen_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Dineen_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Divino_2017,8_strategies,policy_clinical,9090_ER/LA Risk Evaluation and Mitigation Strategy,9090_ER/LA Risk Evaluation and Mitigation Strategy,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Dolan_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Doleac_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Doleac_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Doleac_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Doleac_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,2_decrease
Doleac_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Dorf_2000,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Dormuth_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Dow_2019,2_legislations,policy_theme,9090_minimum wage increases,9090_minimum wage increases,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Dow_2019,2_legislations,policy_theme,9090_minimum wage increases,9090_minimum wage increases,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Dowell_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Dowell_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Dowell_2016,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Dowell_2016,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Dowell_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Dowell_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Dowell_2016,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Dowell_2016,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Dray_2008,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Dray_2008,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Dray_2008,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Dray_2008,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Driscoll_2017,1_legal,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Driscoll_2017,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Drucker_2013,2_legislations,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,2_legislations,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,2_legislations,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,2_legislations,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,2_legislations,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,2_legislations,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,3_regulation,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,3_regulation,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,3_regulation,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,3_regulation,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,3_regulation,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,3_regulation,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,4_government policy,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,4_government policy,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,4_government policy,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,4_government policy,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,4_government policy,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,4_government policy,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,4_government policy,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,4_government policy,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,8_strategies,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,8_strategies,policy_criminal,9090_sentencing and incarceration,9090_sentencing and incarceration,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,8_strategies,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,8_strategies,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,8_strategies,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,8_strategies,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drucker_2013,8_strategies,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Drucker_2013,8_strategies,policy_social,9090_Services avaliable on release from corrections,9090_Services avaliable on release from corrections,1,outcome_type,999_other 1,999,other 1,impact_other,NA,4_detrimental
Drug Policy Alliance_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Dublin_2019,7_programs,policy_theme,9090_Opioid risk reduction initiative,9090_Opioid risk reduction initiative,1,outcome_type,"9090_Injury rates (fractures, concussions, head injuries)",999,other 1,impact_other,"9090_Injury rates (fractures, concussions, head injuries)",0_no change
Ducharme_2008,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,3_beneficial
Duppong_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Durning_2005,1_legal,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,1_legal,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,2_legislations,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,3_regulation,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,4_government policy,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,5_guidelines,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,6_standards,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_theme,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,9090_tort law as an enforcement mechanism for irresponsible marketing/distribution,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Durning_2005,8_strategies,policy_prescription,9090_prescribing practices and enforcement,9090_prescribing practices and enforcement,0,NA,NA,NA,NA,NA,NA,NA
Dutko_2010,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Dzotsenidze_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,4_detrimental
ECDC_2013,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
ECDC_2015,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Edwards_2000,4_government policy,policy_criminal,9090_coercive treatment in corrections,9090_coercive treatment in corrections,0,NA,NA,NA,NA,NA,NA,NA
Edwards_2000,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Edwards_2000,7_programs,policy_criminal,9090_coercive treatment in corrections,9090_coercive treatment in corrections,0,NA,NA,NA,NA,NA,NA,NA
Edwards_2000,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Egan_2004,2_legislations,policy_harm,9090_allows citizens to administer naloxone,9090_allows citizens to administer naloxone,0,NA,NA,NA,NA,NA,NA,NA
Egan_2004,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2002,8_strategies,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_clinical,9090_heroin prescription,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_harm,9090_2_safer use education,9090_2_safer use education,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_harm,"9090_3_low--threshold education, first aid courses","9090_3_low--threshold education, first aid courses",0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_legislative,9090_Measures to reduce public order/nuisance offences,9090_Measures to reduce public order/nuisance offences,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_clinical,9090_heroin prescription,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_harm,9090_2_safer use education,9090_2_safer use education,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_harm,"9090_3_low--threshold education, first aid courses","9090_3_low--threshold education, first aid courses",0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_legislative,9090_Measures to reduce public order/nuisance offences,9090_Measures to reduce public order/nuisance offences,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_clinical,9090_heroin prescription,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_harm,9090_2_safer use education,9090_2_safer use education,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_harm,"9090_3_low--threshold education, first aid courses","9090_3_low--threshold education, first aid courses",0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_legislative,9090_Measures to reduce public order/nuisance offences,9090_Measures to reduce public order/nuisance offences,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2003,8_strategies,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2005,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2005,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2005,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015,2_legislations,policy_legislative,9090_Various alternatives to punishment,9090_Various alternatives to punishment,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015_2,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015_2,8_strategies,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015_2,8_strategies,policy_harm,9090_low-threshold service delivery,9090_low-threshold service delivery,0,NA,NA,NA,NA,NA,NA,NA
EMCDDA_2015_2,8_strategies,policy_harm,9090_2_Naloxone,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Erfanian_2019,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Erfanian_2019,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Erfanian_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Erfanian_2019,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Erickson_2005,4_government policy,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Ernst_2014,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Ernst_2014,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Espelt_2017,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_# of syringes collected,999,other 1,impact_other,9090_# of syringes collected,2_decrease
Espelt_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,9090_# of syringes collected,999,other 1,impact_other,9090_# of syringes collected,2_decrease
Espelt_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_# of syringes collected,999,other 1,impact_other,9090_# of syringes collected,2_decrease
Espelt_2017,8_strategies,policy_harm,3_SIS,3_SIS,1,outcome_type,9090_# of syringes collected,999,other 1,impact_other,9090_# of syringes collected,2_decrease
Ettner_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Ettner_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Ettner_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,0_no change
Evans_2014,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Evans_2014,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Evans_2014,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Evans_2014,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,3_beneficial
Evans_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Evans_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Fairbarin_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Fairbarin_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Fairbarin_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Fairbarin_2015,2_legislations,policy_clinical,9090_voluntary treatment,9090_voluntary treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Fairbarin_2015,2_legislations,policy_clinical,9090_voluntary treatment,9090_voluntary treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Fairbarin_2015,2_legislations,policy_clinical,9090_voluntary treatment,9090_voluntary treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Falcato_2001,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Falcato_2001,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Farrell_2005,2_legislations,policy_criminal,"9090_Forced eradication, and public punishment of transgressors","9090_Forced eradication, and public punishment of transgressors",1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Farrell_2005,2_legislations,policy_legislative,9090_Ban on poppy farming,9090_Ban on poppy farming,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Faryar_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Faryar_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Faryar_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Faryar_2017,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Faryar_2017,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Faryar_2017,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Faryar_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Faryar_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Feder_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Felix_2017,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,0_no change
Felix_2017,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,999_unclear
Felix_2017a,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Felix_2017a,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Felix_2017a,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Felix_2017a,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Felix_2017a,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Fernandez_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,4_detrimental
Ferrara_2012,2_legislations,policy_prescription,9090_differing regulatory approach to prescribing,9090_differing regulatory approach to prescribing,0,NA,NA,NA,NA,NA,NA,NA
Ferrara_2012,3_regulation,policy_prescription,9090_differing regulatory approach to prescribing,9090_differing regulatory approach to prescribing,0,NA,NA,NA,NA,NA,NA,NA
Filies-Away_2014,1_legal,policy_criminal,9090_Indigenous tribal wellness courts,9090_Indigenous tribal wellness courts,0,NA,NA,NA,NA,NA,NA,NA
Filies-Away_2014,7_programs,policy_criminal,9090_Indigenous tribal wellness courts,9090_Indigenous tribal wellness courts,0,NA,NA,NA,NA,NA,NA,NA
Filies-Away_2014,8_strategies,policy_criminal,9090_Indigenous tribal wellness courts,9090_Indigenous tribal wellness courts,0,NA,NA,NA,NA,NA,NA,NA
Fink_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Finley_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Finley_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Finley_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Finley_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Finley_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Fiscella_2004,5_guidelines,policy_criminal,9090_policies and guidelines around withdrawls in jail,9090_policies and guidelines around withdrawls in jail,1,outcome_type,9090_human rights implications,999,other 1,impact_other,9090_human rights implications,4_detrimental
Fiscella_2004,6_standards,policy_criminal,9090_policies and guidelines around withdrawls in jail,9090_policies and guidelines around withdrawls in jail,1,outcome_type,9090_human rights implications,999,other 1,impact_other,9090_human rights implications,4_detrimental
Fischer_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fischer_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Fischer_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Fischer_2013,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fischer_2013,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Fischer_2013,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Fischer_2013,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fischer_2013,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Fischer_2013,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Fischer_2013,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fischer_2013,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Fischer_2013,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Fisher_2012,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fisher_2012,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Fishman_2004,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Fitzgerald_2004,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Fitzgerald_2004,7_programs,policy_law_enforce,2_police presence,2_police presence,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Fitzgerald_2004,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Fitzgerald_2004,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Fitzgerald_2004,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Fitzgerald_2004,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Fitzpatrick_2012,1_legal,policy_legislative,9090_Criminalization of pregnant women uses drugs,9090_pregnancy_related_drug_charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Fitzpatrick_2012,2_legislations,policy_legislative,9090_Criminalization of pregnant women uses drugs,9090_pregnancy_related_drug_charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Fleming_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Fleming_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Fornili_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Franklin_2012,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Franklin_2012,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Freeman_2005,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Freeman_2005,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Freeman_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Freeman_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Freeman_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Friedman_2006,8_strategies,policy_law_enforce,2_police presence,2_police presence,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,4_detrimental
Friedman_2006,8_strategies,policy_law_enforce,9090_# of heroin arrests,9090_# of heroin arrests,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,4_detrimental
Friedman_2006,8_strategies,policy_law_enforce,9090_2_Corrections expenditures,9090_2_Corrections expenditures,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,4_detrimental
Friedman_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Friedman_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,1_increase
Friedman_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_2_service utilization,999,other 1,impact_other,9090_2_service utilization,1_increase
Friedman_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_copayments for SUD vs mental health,999,other 1,impact_other,9090_copayments for SUD vs mental health,0_no change
Fu_2013,7_programs,policy_clinical,9090_forced methadone withdrawal,9090_forced methadone withdrawal,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Furlan_2018,2_legislations,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,2_legislations,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,2_legislations,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,3_regulation,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,3_regulation,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,3_regulation,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,5_guidelines,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_theme,"9090_not specified in article, but mentions that regulations and clinical practice changes were included","9090_not specified in article, but mentions that regulations and clinical practice changes were included",1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Furlan_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Furlan_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Garcia_2014,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Garcia_2014,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Garcia_2014,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Garcia_2016,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Garcia_2016,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Garcia_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Garcia_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Garg_2013,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Garg_2013,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Garin_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Gau_2017,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Gau_2017,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gau_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Gau_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gau_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Gau_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gau_2017,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Gau_2017,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gaubert_2009,7_programs,policy_prescription,9090_Remove drug from hospital formulary,9090_Remove drug from hospital formulary,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Gertner_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Gertner_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Ghobadi_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Ghobadi_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Ghobadi_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gillespie_2017,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Gillespie_2017,1_legal,policy_criminal,9090_Criminal charges for women who use drugs while pregnant,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Gillespie_2017,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Gillespie_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Gillespie_2017,2_legislations,policy_criminal,9090_Criminal charges for women who use drugs while pregnant,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Gillespie_2017,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Gilson_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Gilson_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Giuntella_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_child removals to foster care,999,other 1,impact_other,9090_child removals to foster care,2_decrease
Goldberg_2005,7_programs,policy_theme,9090_Establishment of pain management contract,9090_Establishment of pain management contract,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Goldberg_2005,7_programs,policy_theme,9090_Establishment of pain management contract,9090_Establishment of pain management contract,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Goldberg_2005,7_programs,policy_theme,9090_Establishment of pain management contract,9090_Establishment of pain management contract,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Golichenko_2013,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,4_government policy,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Golichenko_2013,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Gomes_2012,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Gomes_2012,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Gomes_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Gomes_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Gomes_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Gomes_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Gomes_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Gomes_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Gomes_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Goncalves_2015,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Goncalves_2015,8_strategies,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Goncalves_2015,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Gonzalez_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Gonzalez_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Goodman_2008,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,999_unclear
Goodwin_2014,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Goodwin_2014,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Goodwin_2014,2_legislations,policy_legislative,9090_criminalizing drug use while prenanacy and requiring clinician reporting,9090_pregnancy_related_drug_charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Goodwin_2014,3_regulation,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Goodwin_2014,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Goodwin_2014,3_regulation,policy_legislative,9090_criminalizing drug use while prenanacy and requiring clinician reporting,9090_pregnancy_related_drug_charges,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,4_detrimental
Gordon_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Gordon_2016,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Gordon_2016,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Gordon_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Gordon_2016,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Gordon_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Graddy_2017,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Graddy_2017,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Grant_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Grecu_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Grecu_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Grecu_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Green_2006,2_legislations,policy_social,9090_Adoption and safe families act,9090_Adoption and safe families act,1,outcomes_treatment,997_other 3,997,other 3,impact_of_3,NA,0_no change
Green_2006,2_legislations,policy_social,9090_Adoption and safe families act,9090_Adoption and safe families act,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,3_beneficial
Green_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Green_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,3_beneficial
Greenwald_2009,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Greenwald_2009,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Greenwald_2009,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,999_other 1,999,other 1,impact_infect_other,NA,2_decrease
Grogan_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_legislative,4_legalization,4_legalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,2_legislations,policy_international,9090_mechanisims to operatinalize international EU commitments,9090_mechanisims to operatinalize international EU commitments,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_legislative,4_legalization,4_legalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,3_regulation,policy_international,9090_mechanisims to operatinalize international EU commitments,9090_mechanisims to operatinalize international EU commitments,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_legislative,4_legalization,4_legalization,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Gutheil_2016,8_strategies,policy_international,9090_mechanisims to operatinalize international EU commitments,9090_mechanisims to operatinalize international EU commitments,0,NA,NA,NA,NA,NA,NA,NA
Habbouche_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Haegerich_2014,2_legislations,policy_harm,9090_naloxone distribution and overdose prevention/response education,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,3_regulation,policy_harm,9090_naloxone distribution and overdose prevention/response education,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,3_regulation,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,4_government policy,policy_harm,9090_naloxone distribution and overdose prevention/response education,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,4_government policy,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,5_guidelines,policy_harm,9090_naloxone distribution and overdose prevention/response education,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,5_guidelines,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,7_programs,policy_harm,9090_naloxone distribution and overdose prevention/response education,9090_naloxone_access_policies,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,7_programs,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2014,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,4_government policy,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,4_government policy,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,5_guidelines,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,5_guidelines,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Haegerich_2019,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Haffajee_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Haffajee_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,0_no change
Haffajee_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Haffajee_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Haffajee_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Hammett_2014,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,2_legislations,policy_harm,"9090_BBI testing/vaccination, SSTI treatment","9090_BBI testing/vaccination, SSTI treatment",0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,2_legislations,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,3_regulation,policy_harm,"9090_BBI testing/vaccination, SSTI treatment","9090_BBI testing/vaccination, SSTI treatment",0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,3_regulation,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,4_government policy,policy_harm,"9090_BBI testing/vaccination, SSTI treatment","9090_BBI testing/vaccination, SSTI treatment",0,NA,NA,NA,NA,NA,NA,NA
Hammett_2014,4_government policy,policy_clinical,3_availability of OAT - provider - pharmacists,3_availability of OAT - provider - pharmacists,0,NA,NA,NA,NA,NA,NA,NA
Hampton_2011,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,9090_treatment retention,999,other 1,impact_other,9090_treatment retention,1_increase
Hansen_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,9090_Motor vehicle crashes,999,other 1,impact_other,9090_Motor vehicle crashes,0_no change
Hansen_2017,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,9090_Motor vehicle crashes,999,other 1,impact_other,9090_Motor vehicle crashes,0_no change
Hardjasa_2018,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Harrison_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Hartung_2004,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Hartung_2004,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Hartung_2017,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Hartung_2017,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,3_beneficial
Hartung_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Hartung_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Hartung_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Hartung_2018,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Havens_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Hawton_2009,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Hawton_2009,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Hawton_2009,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Hawton_2011,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Hawton_2011,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Hawton_2012,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Hawton_2012,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Hayashi_2013,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,1_increase
Hayashi_2013,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,1_increase
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,1_increase
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Hayes_2015,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Haynes_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Haynes_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Hedrich_2012,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Hedrich_2012,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Hedrich_2012,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Heins_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Heins_2019,2_legislations,policy_prescription,9090_Morphine Equivalent Daily Dose policies,9090_Morphine Equivalent Daily Dose policies,0,NA,NA,NA,NA,NA,NA,NA
Heins_2019,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Heins_2019,4_government policy,policy_prescription,9090_Morphine Equivalent Daily Dose policies,9090_Morphine Equivalent Daily Dose policies,0,NA,NA,NA,NA,NA,NA,NA
Heins_2019,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Heins_2019,5_guidelines,policy_prescription,9090_Morphine Equivalent Daily Dose policies,9090_Morphine Equivalent Daily Dose policies,0,NA,NA,NA,NA,NA,NA,NA
Henderson_2016,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Henderson_2016,2_legislations,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Hewlett_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Hoffman_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Hoffman_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Homenko_2009,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Homenko_2009,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,0_no change
Hopwood_2003,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Hopwood_2003,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,4_detrimental
Hopwood_2003,4_government policy,policy_harm,9090_specifically removal of supplies for methadone injection,9090_specifically removal of supplies for methadone injection,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Hopwood_2003,4_government policy,policy_harm,9090_specifically removal of supplies for methadone injection,9090_specifically removal of supplies for methadone injection,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,4_detrimental
Hora_2008,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Horgan_2008,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Houborg_2014b,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Hough_2003,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Hser_2003,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Hser_2003,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Hser_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Huey_2019,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Huey_2019,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,3_beneficial
Huey_2019,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,9090_2_Safe disposal of syringes,999,other 1,impact_other,9090_2_Safe disposal of syringes,999_unclear
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Hughes_2007,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,2_legislations,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,2_legislations,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,3_regulation,policy_criminal,9090_2_police diversion,9090_2_police diversion,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Hughes_2018,3_regulation,policy_legislative,9090_depenalization,9090_depenalization,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,999_unclear
Husain_2014,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Husain_2014,2_legislations,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Hwang_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Hwang_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Inciardi_2003,8_strategies,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Inciardi_2003,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Inciardi_2009,4_government policy,policy_legislative,9090_FDA approval of generic drugs,9090_FDA approval of generic drugs,1,outcome_type,9090_2_Diversion of fentanyl patches,998,other 2,impact_other_2,9090_2_Diversion of fentanyl patches,0_no change
Inciardi_2009,4_government policy,policy_legislative,9090_FDA approval of generic drugs,9090_FDA approval of generic drugs,1,outcome_type,9090_Diversion of oxycodone,999,other 1,impact_other,9090_Diversion of oxycodone,0_no change
Irvine_2019,3_regulation,policy_harm,4_OPS,4_OPS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irvine_2019,3_regulation,policy_harm,9090_take home nalaxone kits,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irvine_2019,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irvine_2019,7_programs,policy_harm,4_OPS,4_OPS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irvine_2019,7_programs,policy_harm,9090_take home nalaxone kits,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irvine_2019,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,2_decrease
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Irwin_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Israelsson_2011,2_legislations,policy_criminal,9090_compulsory commitment to care,9090_compulsory commitment to care,0,NA,NA,NA,NA,NA,NA,NA
Israelsson_2011,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Israelsson_2012_2,2_legislations,policy_criminal,9090_compulsory commitment to care,9090_compulsory commitment to care,0,NA,NA,NA,NA,NA,NA,NA
Israelsson_2012_2,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Israelsson_2015,2_legislations,policy_criminal,9090_compulsory commitment to care,9090_compulsory commitment to care,0,NA,NA,NA,NA,NA,NA,NA
Israelsson_2015,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Jauncey_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Jauncey_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Johnson_2006,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Johnson_2006,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,0_no change
Johnson_2011,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Jozaghi_2013,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Jozaghi_2013,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Junod_2018,1_legal,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Junod_2018,1_legal,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Junod_2018,1_legal,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Junod_2018,1_legal,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Kaestner_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Kaestner_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Kaestner_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,0_no change
Kaestner_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,0_no change
Kaestner_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,"9090_3_other socio economic outcomes - employment marital status, social welfare cash benefits, weeks worked per year",999,other 1,impact_other,"9090_3_other socio economic outcomes - employment marital status, social welfare cash benefits, weeks worked per year",999_unclear
Kahler_2017,7_programs,policy_clinical,9090_Decline to prescribe opioids in ED and referral to pain clinic,9090_Decline to prescribe opioids in ED and referral to pain clinic,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Kahler_2017,7_programs,policy_clinical,9090_Decline to prescribe opioids in ED and referral to pain clinic,9090_Decline to prescribe opioids in ED and referral to pain clinic,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Kahler_2017,7_programs,policy_clinical,9090_Decline to prescribe opioids in ED and referral to pain clinic,9090_Decline to prescribe opioids in ED and referral to pain clinic,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Kahler_2017,7_programs,policy_clinical,9090_Decline to prescribe opioids in ED and referral to pain clinic,9090_Decline to prescribe opioids in ED and referral to pain clinic,1,outcome_type,999_other 1,999,other 1,impact_other,NA,3_beneficial
Kampschmidt_2015,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Kampschmidt_2015,2_legislations,policy_legislative,9090_Fetal protection criminal statutes,9090_Fetal protection criminal statutes,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Kampschmidt_2015,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Kampschmidt_2015,8_strategies,policy_legislative,9090_Fetal protection criminal statutes,9090_Fetal protection criminal statutes,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Kattan_2016,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Kattan_2016,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Kattan_2016,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Katz_2009,7_programs,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Katz_2009,7_programs,policy_clinical,9090_avaliability of prescription heroin,9090_prescription_heroin,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Katz_2009,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Katz_2009,8_strategies,policy_clinical,9090_avaliability of prescription heroin,9090_prescription_heroin,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Kaufman_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Keast_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Keast_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Keast_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Keast_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Keast_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Keene_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,3_beneficial
Kennedy-Hendrick_2016,2_legislations,policy_criminal,9090_arrest and prosecution those involved with 'pill mills',9090_arrest and prosecution those involved with 'pill mills',1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Kennedy-Hendrick_2016,2_legislations,policy_criminal,9090_arrest and prosecution those involved with 'pill mills',9090_arrest and prosecution those involved with 'pill mills',1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Kennedy-Hendrick_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Kennedy-Hendrick_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Kennedy_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Kennedy_2017,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Kennedy_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Kennedy_2019,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Kennedy_2019,6_standards,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Kennedy_2019,6_standards,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Kerr_2006,7_programs,policy_harm,3_SIS,3_SIS,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Khobrani_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Khobrani_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Khruakham_2016,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Khruakham_2016,8_strategies,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Khruakham_2016,8_strategies,policy_legislative,9090_control of illicit drugs through monitoring of chemicals and precursors,9090_control of illicit drugs through monitoring of chemicals and precursors,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Khruakham_2016,8_strategies,policy_social,9090_Reintegrative programs - job opportunities and vocational training,9090_Reintegrative programs - job opportunities and vocational training,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Khruakham_2016,8_strategies,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,1_increase
Kilby_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Kim_2016,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,9090_opioids detected in drivers of fatal crashes,999,other 1,impact_other,9090_opioids detected in drivers of fatal crashes,999_unclear
Kinnard_2014,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_illegal,997_other 3,997,other 3,impact_dui_2,NA,2_decrease
Kinnard_2014,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_illegal,998_other 2,998,other 2,impact_dui_2,NA,2_decrease
Kinnard_2014,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Kinner_2013,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Kinsman_2018,2_legislations,policy_prescription,9090_authority to administer Naloxone by EMTs,9090_authority to administer Naloxone by EMTs,0,NA,NA,NA,NA,NA,NA,NA
Kinsman_2018,3_regulation,policy_prescription,9090_authority to administer Naloxone by EMTs,9090_authority to administer Naloxone by EMTs,0,NA,NA,NA,NA,NA,NA,NA
Kline_2019,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Kline_2019,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Knudsen_2015,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_Number of physicians waivered to prescribe buprenorphine,999,other 1,impact_other,9090_Number of physicians waivered to prescribe buprenorphine,999_unclear
Knudsen_2015a,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Knudsen_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,999_unclear
Knudsen_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Kopf_2014,2_legislations,policy_law_enforce,2_police presence,2_police presence,0,NA,NA,NA,NA,NA,NA,NA
Kopf_2014,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,1_legal,policy_social,9090_Child protective services,9090_Child protective services,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Korn_2016,2_legislations,policy_social,9090_Child protective services,9090_Child protective services,0,NA,NA,NA,NA,NA,NA,NA
Kozhimannil_2019,3_regulation,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,3_regulation,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,3_regulation,policy_legislative,9090_provider reporting requirements,9090_provider reporting requirements,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,3_regulation,policy_legislative,9090_provider reporting requirements,9090_provider reporting requirements,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,4_government policy,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,4_government policy,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,4_government policy,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,4_government policy,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,4_government policy,policy_legislative,9090_provider reporting requirements,9090_provider reporting requirements,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,4_government policy,policy_legislative,9090_provider reporting requirements,9090_provider reporting requirements,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Kozhimannil_2019,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Kozhimannil_2019,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Krakauer_2015,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Krakauer_2015,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Krakauer_2015,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Krakauer_2015,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Kramer_2015,4_government policy,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Kropp_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Kruithof_2017,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Kruithof_2017,2_legislations,policy_criminal,9090_other types of diversion,9090_other types of diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Kruithof_2017,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Kumar_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Kuo_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Kuo_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Kuo_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Kushel_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Kushel_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Kushel_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Kwok_2017,4_government policy,policy_prescription,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Kwok_2017,4_government policy,policy_prescription,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,999_unclear
Kwok_2017,4_government policy,policy_prescription,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Kwok_2017,4_government policy,policy_prescription,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Ladd_2017,3_regulation,policy_theme,9090_NP scope of practice,9090_NP scope of practice,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Ladd_2017,3_regulation,policy_theme,9090_NP scope of practice,9090_NP scope of practice,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Ladd_2017,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Ladd_2017,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Lambdin_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,9090_overdose education and naloxone distribution,999,other 1,impact_other,9090_overdose education and naloxone distribution,1_increase
Lambdin_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,9090_overdose education and naloxone distribution,999,other 1,impact_other,9090_overdose education and naloxone distribution,1_increase
Larance_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_3_adverse effects,997,other 3,impact_other_3,9090_3_adverse effects,4_detrimental
Larance_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_client perceptions of transfer to the new formulation,999,other 1,impact_other,9090_client perceptions of transfer to the new formulation,4_detrimental
Larance_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_client perceptions of transfer to the new formulation,999,other 1,impact_other,9090_client perceptions of transfer to the new formulation,999_unclear
Larance_2015_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Larance_2015_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,0_no change
Larance_2015_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,0_no change
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,999_unclear
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Larance_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Larkin_2016,1_legal,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Larkin_2016,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Larkin_2016,1_legal,policy_theme,9090_Probation,9090_Probation,0,NA,NA,NA,NA,NA,NA,NA
Larkin_2016,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Larkin_2016,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Larkin_2016,2_legislations,policy_theme,9090_Probation,9090_Probation,0,NA,NA,NA,NA,NA,NA,NA
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,1_increase
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,1_increase
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,1_increase
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,1_increase
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Larochelle_2015,2_legislations,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Lasnier_2010,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Lasnier_2010,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Lasnier_2010,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Lasnier_2010,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Latimore_2017,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_willingness to call 911 during an OD,999,other 1,impact_other,9090_willingness to call 911 during an OD,1_increase
Latimore_2017,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_willingness to call 911 during an OD,999,other 1,impact_other,9090_willingness to call 911 during an OD,3_beneficial
Laws_2005,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Laws_2005,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Levy_2008,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Levy_2008,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Levy_2008,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Levy_2008,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Li_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Li_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,4_detrimental
Liang_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Liang_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Liang_2019_2,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Liang_2019_2,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Liang_2019_2,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,1_increase
Liang_2019_2,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Liang_2019_2,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Liang_2019_2,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,1_increase
Lilley_2013,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Lilley_2016,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_arrests,999,other 1,impact_other,9090_arrests,1_increase
Lilley_2019,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_arrest rates,999,other 1,impact_other,9090_arrest rates,1_increase
Lin_2017,7_programs,policy_clinical,9090_dashboard that notes high dose opioid prescribing and concurrent benzodiazepine use,9090_dashboard that notes high dose opioid prescribing and concurrent benzodiazepine use,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Lin_2017,7_programs,policy_clinical,9090_dashboard that notes high dose opioid prescribing and concurrent benzodiazepine use,9090_dashboard that notes high dose opioid prescribing and concurrent benzodiazepine use,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
Lin_2017_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Lin_2017_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,3_beneficial
Lin_2017_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_2_perceived utility,999,other 1,impact_other,9090_2_perceived utility,999_unclear
Lin_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Lin_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Lin_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Liu_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Livingstone_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Livingstone_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Lloyd_2017,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Lo_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,9090_compliance with opioid therapy,999,other 1,impact_other,9090_compliance with opioid therapy,0_no change
Lofgren_2011,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Lofgren_2011,2_legislations,policy_criminal,9090_other drug reform laws that focused on treatment instead of incarceration,9090_other drug reform laws that focused on treatment instead of incarceration,0,NA,NA,NA,NA,NA,NA,NA
Lofgren_2011,3_regulation,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Lofgren_2011,3_regulation,policy_criminal,9090_other drug reform laws that focused on treatment instead of incarceration,9090_other drug reform laws that focused on treatment instead of incarceration,0,NA,NA,NA,NA,NA,NA,NA
Logan_2001,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Logan_2001,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,997_other 3,997,other 3,impact_other_3,NA,3_beneficial
Logan_2001,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_3_costs to society,998,other 2,impact_other_2,9090_3_costs to society,3_beneficial
Logan_2001,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_2_income,999,other 1,impact_other,9090_2_income,2_decrease
Lollar_2017,1_legal,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_2_Is there a long term health impact on fetus from illegal drug use by pregnant women?,998,other 2,impact_other_2,9090_2_Is there a long term health impact on fetus from illegal drug use by pregnant women?,0_no change
Lollar_2017,1_legal,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_Does legal prosecution of pregnant women reduce substance use among pregnant women in Tennesse?,999,other 1,impact_other,9090_Does legal prosecution of pregnant women reduce substance use among pregnant women in Tennesse?,0_no change
Lollar_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_2_Is there a long term health impact on fetus from illegal drug use by pregnant women?,998,other 2,impact_other_2,9090_2_Is there a long term health impact on fetus from illegal drug use by pregnant women?,0_no change
Lollar_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_Does legal prosecution of pregnant women reduce substance use among pregnant women in Tennesse?,999,other 1,impact_other,9090_Does legal prosecution of pregnant women reduce substance use among pregnant women in Tennesse?,0_no change
Loong_2019,2_legislations,policy_criminal,9090_mental health courts,9090_mental health courts,1,outcome_type,9090_2_police contact,998,other 2,impact_other_2,9090_2_police contact,999_unclear
Loong_2019,2_legislations,policy_criminal,9090_mental health courts,9090_mental health courts,1,outcome_type,9090_recividism,999,other 1,impact_other,9090_recividism,2_decrease
Losby_2016,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Lucas_2017,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Lucas_2017,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,5_guidelines,policy_harm,5_drug testing,5_drug testing,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,5_guidelines,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,7_programs,policy_harm,5_drug testing,5_drug testing,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,7_programs,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,999_unclear
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,3_beneficial
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,3_beneficial
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,999_unclear
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Luyt_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Lyapustina_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Lyapustina_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Lyapustina_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Lyapustina_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,999_unclear
Macdonald_2001a,2_legislations,policy_social,3_restrictions,3_restrictions,0,NA,NA,NA,NA,NA,NA,NA
MacDonald_2019,7_programs,policy_theme,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
MacDonald_2019,7_programs,policy_theme,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
MacDonald_2019,7_programs,policy_theme,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
MacDonald_2019,7_programs,policy_theme,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
MacDonald_2019,7_programs,policy_theme,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,9090_doctor shopping - letters sent to prescribers for that were identified as receiving opioids from more than 3 prescribers/pharmacies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
MacDonald_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
MacDonald_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
MacDonald_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
MacDonald_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
MacDonald_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
MacLean_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
MacLean_2018_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_3_Prescriptions for SUD medications reimbursed by Medicaid,997,other 3,impact_other_3,9090_3_Prescriptions for SUD medications reimbursed by Medicaid,1_increase
MacLean_2018_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_2_Number of patients not covered by insurance,998,other 2,impact_other_2,9090_2_Number of patients not covered by insurance,2_decrease
MacLean_2018_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_Medicaid coverage and payments,999,other 1,impact_other,9090_Medicaid coverage and payments,1_increase
Majtabai_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Malkin_2001,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Malkin_2001,2_legislations,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Malkin_2001,4_government policy,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Malkin_2001,4_government policy,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Malkin_2001,7_programs,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Malkin_2001,7_programs,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Mallatt_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Mallatt_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Mallatt_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Mallatt_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Mallatt_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mallatt_2019_2,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mallatt_2019_2,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mallatt_2019_2,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mallatt_2019_2,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Mallya_2013,7_programs,policy_clinical,9090_witnessed vs unwitnessed urine drug screens,9090_witnessed vs unwitnessed urine drug screens,1,outcome_type,9090_opioid-positive urine drug screens,999,other 1,impact_other,9090_opioid-positive urine drug screens,1_increase
Mallya_2013,7_programs,policy_clinical,9090_witnessed vs unwitnessed urine drug screens,9090_witnessed vs unwitnessed urine drug screens,1,outcome_type,9090_opioid-positive urine drug screens,999,other 1,impact_other,9090_opioid-positive urine drug screens,999_unclear
Mandiberg_2014,2_legislations,policy_legislative,9090_Federal housing law,9090_Federal housing law,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mandiberg_2014,2_legislations,policy_legislative,9090_2_Rehabilitation act (RA),9090_2_Rehabilitation act (RA),1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mandiberg_2014,2_legislations,policy_legislative,9090_3_Americans with disabilities act (ADA),9090_3_Americans with disabilities act (ADA),1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mandiberg_2014,7_programs,policy_legislative,9090_Federal housing law,9090_Federal housing law,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mandiberg_2014,7_programs,policy_legislative,9090_2_Rehabilitation act (RA),9090_2_Rehabilitation act (RA),1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mandiberg_2014,7_programs,policy_legislative,9090_3_Americans with disabilities act (ADA),9090_3_Americans with disabilities act (ADA),1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Margolis_2009,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Margolis_2009,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
Margolis_2010,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Margolis_2010,6_standards,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Marotta_2016,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Marotta_2016,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,3_beneficial
Marotta_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Marotta_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,3_beneficial
Marshall_2011,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Marshall_2011,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Martello_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Martello_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,997_other 3,997,other 3,impact_non_pres_other,NA,0_no change
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,997_other 3,997,other 3,impact_non_pres_other,NA,1_increase
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,998_other 2,998,other 2,impact_non_pres_other,NA,0_no change
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,998_other 2,998,other 2,impact_non_pres_other,NA,1_increase
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,0_no change
Martin_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,1_increase
Martinez_2007,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_arrests for syringe possession,999,other 1,impact_other,9090_arrests for syringe possession,1_increase
Maughan_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Mazerolle_2006,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
McAuley_2015,7_programs,policy_harm,9090_Take home naloxone,9090_naloxone_access_policies,1,outcome_type,9090_Nalaxone use,999,other 1,impact_other,9090_Nalaxone use,3_beneficial
McAuley_2017,7_programs,policy_harm,9090_national naloxone programme,9090_national naloxone programme,1,outcome_type,9090_Ambulance call outs,999,other 1,impact_other,9090_Ambulance call outs,0_no change
McCary_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
McCary_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
McCary_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,1_increase
McCary_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,9090_2_# received psycho-social support for opioid use disorder,999,other 1,impact_other,9090_2_# received psycho-social support for opioid use disorder,1_increase
McClellan_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
McClellan_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
McClellan_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
McClellan_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
McClellan_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
McClellan_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
McClellan_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
McClellan_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
McClellan_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
McClellan_2018,4_government policy,policy_legislative,5_first responders,5_first responders,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
McClellan_2018,4_government policy,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
McClellan_2018,4_government policy,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
McClure_2019,1_legal,policy_criminal,9090_prosecution of doctors for chronically over-prescribing opioids (pill mills),9090_prosecution of doctors for chronically over-prescribing opioids (pill mills),0,NA,NA,NA,NA,NA,NA,NA
McConnell_2012,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,999_unclear
McConnell_2012_2,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
McConnell_2012_2,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,0_no change
McConnell_2012_2,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
McFarland_2005,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,"9090_retention in treatment, abstinence after discharge, completion of treatment, readmission",999,other 1,impact_other,"9090_retention in treatment, abstinence after discharge, completion of treatment, readmission",0_no change
McGerald_2009,7_programs,policy_theme,9090_Streamlined prescribing writing process,9090_Streamlined prescribing writing process,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
McGerald_2009,7_programs,policy_theme,9090_Streamlined prescribing writing process,9090_Streamlined prescribing writing process,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
McGinty_2015,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,1_increase
McGinty_2015,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,1_increase
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
McInerney_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
McKenna_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
McKenzie_2005,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
McMichael_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
McMichael_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
McMichael_2018_2,3_regulation,policy_theme,9090_NP scope of practice,9090_NP scope of practice,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
McMichael_2018_2,3_regulation,policy_theme,9090_NP scope of practice,9090_NP scope of practice,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
McMichael_2018_2,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
McMichael_2018_2,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
McSweeny_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
McSweeny_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
McSweeny_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
McSweeny_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
McSweeny_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
McSweeny_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
McSweeny_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
McSweeny_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
McSweeny_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
McSweeny_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Meara_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Meara_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Meinhofer_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Meinhofer_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,3_beneficial
Meinhofer_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Meinhofer_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Meinhofer_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,1_access,1,access,impact_access,NA,0_no change
Meisenberg_2018,7_programs,policy_clinical,9090_Physician and public education,9090_Physician and public education,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Meisenberg_2018,7_programs,policy_clinical,9090_Physician and public education,9090_Physician and public education,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Merlo_2011,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,9090_Opioid relapse,999,other 1,impact_other,9090_Opioid relapse,3_beneficial
Meyerson_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Michels_2007,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Miller_2004,7_programs,policy_clinical,9090_Prescription heroin,9090_prescription_heroin,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Miller_2004,7_programs,policy_clinical,9090_Prescription heroin,9090_prescription_heroin,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Miller_2016,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Miller_2016,2_legislations,policy_legislative,9090_State-based opioid overdose response program,9090_State-based opioid overdose response program,0,NA,NA,NA,NA,NA,NA,NA
Miller_2016,5_guidelines,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Miller_2016,5_guidelines,policy_legislative,9090_State-based opioid overdose response program,9090_State-based opioid overdose response program,0,NA,NA,NA,NA,NA,NA,NA
Milloy_2008,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Minhee_2019,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Miron_2003,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Mitchell_2012,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mitchell_2012,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Mitchell_2012_2,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Mohammadi_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Mohammadi_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
Mojtabai_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Mojtabai_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Mojtabai_2019b,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Monaghan_2013,7_programs,policy_social,9090_Welfare-to-work program,9090_Welfare-to-work program,0,NA,NA,NA,NA,NA,NA,NA
Moore_2007,7_programs,policy_criminal,9090_prison,9090_prison,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Moore_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Moore_2007,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Morden_2008,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Morden_2008,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Morgan_2015,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,2_decrease
Moride_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Moride_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Moride_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Moride_2019,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Moride_2019,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Moride_2019,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Moride_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Moride_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Moride_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Moride_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Moride_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Moride_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Morse_2011,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,0_no change
Mospan_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Mospan_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Mospan_2018,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Mospan_2018,8_strategies,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Moyo_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,997_other 3,997,other 3,impact_pres_other,NA,0_no change
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,997_other 3,997,other 3,impact_pres_other,NA,2_decrease
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,0_no change
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Moyo_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Mulcahy_2017,3_regulation,policy_prescription,9090_Creation of a formulary,9090_Creation of a formulary,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Mulrooney_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Murimi_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Murimi_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Murphy_2017,7_programs,policy_clinical,9090_ED care coordination program,9090_ED care coordination program,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Musselwhite_2010,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Musselwhite_2010,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Musselwhite_2010,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Musselwhite_2010,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Myer_2018,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Myer_2018,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Nagar_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,1_increase
Nagar_2015,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_illegal,2_drug use related injuries,2,drug use related injuries,impact_dui,NA,1_increase
Nam_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Nam_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Naumann_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,1_increase
Naumann_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Naumann_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Naumann_2018,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Naumann_2018_2,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Naumann_2018_2,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Naumann_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Naumann_2019,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Neven_2016,7_programs,policy_clinical,9090_ED care coordination program,9090_ED care coordination program,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Neven_2016,7_programs,policy_clinical,9090_ED care coordination program,9090_ED care coordination program,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Nguyen_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,9090_accidental overdose ED and inpatient visits,999,other 1,impact_other,9090_accidental overdose ED and inpatient visits,1_increase
Nicosia_2017,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_probability of a prison sentence,999,other 1,impact_other,9090_probability of a prison sentence,0_no change
Nicosia_2017,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_probability of a prison sentence,999,other 1,impact_other,9090_probability of a prison sentence,2_decrease
Niv_2009,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,1_access,1,access,impact_access,NA,999_unclear
Nordt_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Nordt_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,0_no change
Nordt_2010,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Nordt_2010,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,4_detrimental
Nordt_2010,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Nordt_2010,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,4_detrimental
Northrup_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Northrup_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Novak_2012,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Obadia_2001,4_government policy,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Obrien_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,999_unclear
Obrien_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
OConner_2011,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
OConnor_2019,1_legal,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
OConnor_2019,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Oehler_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Oehler_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Olfson_2018,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Olsen_2006,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Olson_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,2_legislations,policy_harm,9090_Nalxone access law,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,2_legislations,policy_legislative,9090_2_pain clinic laws,9090_2_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_harm,9090_Nalxone access law,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_legislative,9090_2_pain clinic laws,9090_2_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,3_regulation,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_harm,9090_Nalxone access law,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_legislative,9090_2_pain clinic laws,9090_2_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Olson_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Osborn_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Ozluk_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Ozluk_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Ozluk_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Ozluk_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Page_2018,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Page_2018,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Palmateer_2014,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Palmateer_2014,7_programs,policy_harm,9090_other clean paraphinalia,9090_other clean paraphinalia,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Palmateer_2014,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,2_HepC,2,HepC,impact_hepc,NA,2_decrease
Paone_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paone_2015,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paone_2015,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paone_2015,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paone_2015,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,8_strategies,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paone_2015,8_strategies,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Paone_2015,8_strategies,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Pardo_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Pardo_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Park_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_alcohol induced mortality,999,other 1,impact_other,9090_alcohol induced mortality,0_no change
Parsons_2014,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Parsons_2014,2_legislations,policy_criminal,9090_Changes in mandatory sentencing structure,9090_Changes in mandatory sentencing structure,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Patrick_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Paulozzi_2011,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Paulozzi_2011,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Pauly_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Peacock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Peacock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Peacock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Peacock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Peakcock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Peakcock_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Pearson_2015,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,9090_Medicaid coverage for abuse deterrent formulations / extended release vs generic opioids,999,other 1,impact_other,9090_Medicaid coverage for abuse deterrent formulations / extended release vs generic opioids,2_decrease
Pedersen_2011,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Pedersen_2011,4_government policy,policy_clinical,9090_Mandate that treatment (OAT or residential) must begin within 14 days after a request,9090_Mandate that treatment (OAT or residential) must begin within 14 days after a request,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Penm_2017,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,4_government policy,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Penm_2017,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Penm_2017,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Perez-Munoz_2017,2_legislations,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Perngmark_2007,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,4_government policy,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,4_government policy,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,4_government policy,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,4_government policy,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perngmark_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Perngmark_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Perngmark_2007,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Perry_2009,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,4_detrimental
Peterson_2019,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,4_detrimental
Peterson_2019,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Phillips_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Phillips_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Phillips_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Phillips_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Pinkerton_2010,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Pinkerton_2010,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Pitt_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,2_legislations,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,3_regulation,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,4_government policy,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,5_guidelines,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pitt_2018,7_programs,policy_prescription,9090_Excess drug disposal,9090_Excess drug disposal,1,outcome_type,999_other 1,999,other 1,impact_other,NA,999_unclear
Pohl_2018,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Pohl_2018,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pohl_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Pohl_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pohl_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Pohl_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pohl_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Pohl_2018,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,999_unclear
Pombo_2016,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcomes_treatment,1_access,1,access,impact_access,NA,999_unclear
Pombo_2016,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Pombo_2016,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Ponnapalli_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Ponnapalli_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Ponnapalli_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Popovici_2018,3_regulation,policy_theme,9090_2_doctor shopping laws,9090_2_doctor shopping laws,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Popovici_2018,3_regulation,policy_theme,9090_2_doctor shopping laws,9090_2_doctor shopping laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Popovici_2018,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Popovici_2018,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Popovici_2018_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Popovici_2018_2,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Potier_2014,3_regulation,policy_harm,3_SIS,3_SIS,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,0_no change
Potier_2014,3_regulation,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Potier_2014,3_regulation,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Powell_2011,3_regulation,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Powell_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Powell_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,1_increase
Powell_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Powell_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Pradel_2009,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Rafful_2018,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Raji_2017,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Raji_2017,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Raji_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Ranapurwala_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Ranapurwala_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Rasubala_2015,2_legislations,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Rasubala_2015,2_legislations,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcome_otc,2_non-prescription drug use,2,non-prescription drug use,impact_otc,NA,1_increase
Rasubala_2015,2_legislations,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Rasubala_2015,3_regulation,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Rasubala_2015,3_regulation,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcome_otc,2_non-prescription drug use,2,non-prescription drug use,impact_otc,NA,1_increase
Rasubala_2015,3_regulation,policy_prescription,9090_Registry of schedule II drugs consulted before script,9090_Registry of schedule II drugs consulted before script,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Rees_2019,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Rees_2019,2_legislations,policy_harm,9090_naloxone,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Rees_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Rees_2019,2_legislations,policy_legislative,5_first responders,5_first responders,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Reifler_2012,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Reifler_2012,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Reisman_2009,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Reisman_2009,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Reisman_2009,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,2_decrease
Reitan_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Rengifo_2010,2_legislations,policy_clinical,7_compulsory_treatment,7_compulsory_treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Rengifo_2010,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Reset_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Resiak_2016,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Resiak_2016,7_programs,policy_criminal,9090_diversion,9090_diversion,0,NA,NA,NA,NA,NA,NA,NA
Resiak_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Resiak_2016,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Rhodes_2015,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,2_decrease
Rich_2015,7_programs,policy_clinical,9090_Discontinuation of methadone maintenance-treatment programme after incarceration,9090_Discontinuation of methadone maintenance-treatment programme after incarceration,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Riggs_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Riggs_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Rinaldo_2013,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Ringwalt_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Ringwalt_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Ringwalt_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Ringwalt_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,999_unclear
Ritter_2005,4_government policy,policy_clinical,9090_take-away methadone policies,9090_take-away methadone policies,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Roberts_2014,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Roberts_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Roberts_2016,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Robinson_2010,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Robles_2001,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Robles_2001,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Robles_2001,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Robles_2001,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Robles_2001,7_programs,policy_clinical,9090_Patient determined methadone dose,9090_Patient determined methadone dose,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Robles_2001,7_programs,policy_clinical,9090_Patient determined methadone dose,9090_Patient determined methadone dose,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Robles_2001,7_programs,policy_clinical,9090_Patient determined methadone dose,9090_Patient determined methadone dose,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Robles_2001,7_programs,policy_clinical,9090_Patient determined methadone dose,9090_Patient determined methadone dose,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,1_increase
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,4_detrimental
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_2_Methadone/buprenorphine related mortality,999,other 1,impact_other,9090_2_Methadone/buprenorphine related mortality,2_decrease
Romelsjo_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_2_Methadone/buprenorphine related mortality,999,other 1,impact_other,9090_2_Methadone/buprenorphine related mortality,3_beneficial
Rosenblum_2002,1_legal,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Rosenblum_2002,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Rosenblum_2002,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Rosenblum_2002,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Rossiter_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Rossiter_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Rossiter_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Rossiter_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Rousseau_2017,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Rudolph_2011,5_guidelines,policy_clinical,"9090_Discharge-on-scene policy, where Medical Emergency Care Unit (MECU) are allowed to administer naloxone in case of opioid overdose, and if patient shows a substantial and lasting improvement in vital signs, they are released on scene (not hospitalised)","9090_Discharge-on-scene policy, where Medical Emergency Care Unit (MECU) are allowed to administer naloxone in case of opioid overdose, and if patient shows a substantial and lasting improvement in vital signs, they are released on scene (not hospitalised)",1,outcome_type,9090_48-hour mortality rates after administration of naloxone and discharge-on-scene,999,other 1,impact_other,9090_48-hour mortality rates after administration of naloxone and discharge-on-scene,0_no change
Russoniello_2012,1_legal,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Russoniello_2012,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Rutkow_2015,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Rutkow_2015,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Sacks_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Sacks_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Salmon_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Salmon_2009,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Saloner_2016,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Saloner_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Saloner_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,2_decrease
Saloner_2018,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,4_government policy,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,4_government policy,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,5_guidelines,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,5_guidelines,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,5_guidelines,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,5_guidelines,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Saloner_2018,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Saloner_2018,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Saloner_2018,7_programs,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Sander_2016,3_regulation,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Sander_2016,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Sandlilands_2008,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Sankey_2016,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,0_no change
Sankey_2016,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Sankey_2016,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Sankey_2016,4_government policy,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Sanmartin_2019,4_government policy,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_Foster care admissions,999,other 1,impact_other,9090_Foster care admissions,1_increase
Santistevan_2018,7_programs,policy_clinical,9090_removal default # tablets prescribed in ED,9090_removal default # tablets prescribed in ED,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Santistevan_2018,7_programs,policy_clinical,9090_removal default # tablets prescribed in ED,9090_removal default # tablets prescribed in ED,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,3_beneficial
Saulle_2017,4_government policy,policy_clinical,9090_supervised dosing policies,9090_supervised dosing policies,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Saunders_2014,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,0_no change
Saunders_2014,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Schackman_2006,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_treatment,1_access,1,access,impact_access,NA,4_detrimental
Schaffer_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Schaffer_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Schaffer_2018,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Schaffer_2019,3_regulation,policy_social,9090_subsidizing of controlledrelease oxycodone,9090_subsidizing of controlledrelease oxycodone,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Schaffer_2019,3_regulation,policy_social,9090_subsidizing of controlledrelease oxycodone,9090_subsidizing of controlledrelease oxycodone,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Schill_2018,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Schultz_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Schultz_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Schwartz_2013,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Seago_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Seago_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,3_beneficial
Sears_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Sears_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,3_beneficial
Sears_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Sellars_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Sessler_2014,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Severtson_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Severtson_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,998_other 2,998,other 2,impact_pres_other,NA,2_decrease
Severtson_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Severtson_2013,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Severtson_2016,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Sevigny_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_2_time spent in prision,998,other 2,impact_other_2,9090_2_time spent in prision,0_no change
Sevigny_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,9090_incarceration rate,999,other 1,impact_other,9090_incarceration rate,2_decrease
Shaffer_2011,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Shah_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
Shah_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Sham_2011,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Sham_2011,2_legislations,policy_criminal,9090_CAP Laws for parents not locking away prescriptions,9090_CAP Laws for parents not locking away prescriptions,0,NA,NA,NA,NA,NA,NA,NA
Sham_2011,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_criminal,9090_diversion,9090_diversion,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,2_legislations,policy_clinical,9090_HAT,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_criminal,9090_diversion,9090_diversion,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,3_regulation,policy_clinical,9090_HAT,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_criminal,9090_diversion,9090_diversion,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,0,NA,NA,NA,NA,NA,NA,NA
Sharareh_2019,7_programs,policy_clinical,9090_HAT,9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
Sharma_2017,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Sharma_2017,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Sharp_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Sharp_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sharp_2018,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Shearer_2007,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Shepherd_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Shi_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Shi_2017,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,2_decrease
Shi_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Shi_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,NA
Shi_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Shi_2019,3_regulation,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,NA
Shi_2019,7_programs,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Shi_2019,7_programs,policy_legislative,4_legalization,4_legalization,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,NA
Shover_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,1_increase
Shover_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Showalter_2018,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Shumway_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Shumway_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Shumway_2019,8_strategies,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Siddiqui_2015,2_legislations,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_type,9090_Pharmacy syringe sales,999,other 1,impact_other,9090_Pharmacy syringe sales,1_increase
Simojoki_2008,3_regulation,policy_clinical,9090_forced transfer from Subutex to Suboxone after it was made available with special licence,9090_forced transfer from Subutex to Suboxone after it was made available with special licence,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Simoni-Wastila_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
Simoni-Wastila_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Skinner_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Skinner_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Skinner_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Skinner_2016,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,3_beneficial
SKodbo_2007,7_programs,policy_criminal,9090_Diversion,9090_diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
SKodbo_2007,7_programs,policy_criminal,9090_Diversion,9090_diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Skretting_2010,3_regulation,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Skretting_2010,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Smith_2012,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Smith_2012,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Smith_2015,1_legal,policy_criminal,9090_Safe harbour act,9090_Safe harbour act,1,outcome_type,9090_Criminalization of maternal drug use,999,other 1,impact_other,9090_Criminalization of maternal drug use,4_detrimental
Smith_2015,2_legislations,policy_criminal,9090_Safe harbour act,9090_Safe harbour act,1,outcome_type,9090_Criminalization of maternal drug use,999,other 1,impact_other,9090_Criminalization of maternal drug use,4_detrimental
Smithson_2005,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
Smithson_2005,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,999_other 1,999,other 1,impact_non_pres_other,NA,2_decrease
Smyth_2015,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Smyth_2019,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,1,outcome_type,9090_drug related psychiatric admissions,999,other 1,impact_other,9090_drug related psychiatric admissions,2_decrease
Snider_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Socias_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,1_increase
Socias_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Socias_2017,3_regulation,policy_prescription,9090_restrictions in pharmacy delivery services,9090_restrictions in pharmacy delivery services,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,1_increase
Socias_2017,3_regulation,policy_prescription,9090_restrictions in pharmacy delivery services,9090_restrictions in pharmacy delivery services,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Sohn_2019,2_legislations,policy_harm,9090_mandated co-prescriptions of naloxone,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Sohn_2019,4_government policy,policy_harm,9090_mandated co-prescriptions of naloxone,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Soni_2018,7_programs,policy_prescription,9090_Effect of increase prescription prices on opioid consumption,9090_Effect of increase prescription prices on opioid consumption,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Soni_2018,7_programs,policy_prescription,9090_Effect of increase prescription prices on opioid consumption,9090_Effect of increase prescription prices on opioid consumption,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Soni_2018,7_programs,policy_prescription,9090_Effect of increase prescription prices on opioid consumption,9090_Effect of increase prescription prices on opioid consumption,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,3_beneficial
Soper_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Soper_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Soper_2018,7_programs,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,2_decrease
Sorensen_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Sorensen_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,2_decrease
Sorensen_2009,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,999_unclear
Spooner_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Spooner_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Spooner_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Spooner_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Spooner_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Spooner_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Spooner_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Spooner_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Spooner_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Spooner_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Spooner_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Spooner_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Spooner_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Spooner_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Spooner_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Spooner_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Srubar_2015,8_strategies,policy_international,1_international drug treaties,1_international drug treaties,0,NA,NA,NA,NA,NA,NA,NA
Srubar_2015,8_strategies,policy_international,9090_International cooperation,9090_International cooperation,0,NA,NA,NA,NA,NA,NA,NA
Srubar_2015,8_strategies,policy_international,9090_2_Extradition,9090_2_Extradition,0,NA,NA,NA,NA,NA,NA,NA
Srubar_2015,8_strategies,policy_international,9090_3_Mutual legal assistance,9090_3_Mutual legal assistance,0,NA,NA,NA,NA,NA,NA,NA
Stanos_2012,8_strategies,policy_clinical,9090_ER/LA Risk Evaluation and Mitigation Strategy,9090_ER/LA Risk Evaluation and Mitigation Strategy,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,1_legal,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,1_legal,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,1_legal,policy_clinical,9090_pain management,9090_pain management,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,2_legislations,policy_clinical,9090_pain management,9090_pain management,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,5_guidelines,policy_clinical,9090_pain management,9090_pain management,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,6_standards,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,6_standards,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Stark_2002,6_standards,policy_clinical,9090_pain management,9090_pain management,0,NA,NA,NA,NA,NA,NA,NA
Steckler_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Steckler_2019,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Steffen_2016,1_legal,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Steffen_2016,1_legal,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Steffen_2016,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Steffen_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Stein_2014,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Stein_2015,4_government policy,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Stein_2015,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Stein_2015,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Stein_2015,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Stemen_2012,2_legislations,policy_clinical,7_compulsory_treatment,7_compulsory_treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Stemen_2012,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Stevenson_2002,2_legislations,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Stevenson_2002,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Stevenson_2002,7_programs,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Stevenson_2002,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,2_legislations,policy_harm,9090_Treatment for pregnant women/mothers with addictions,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,2_legislations,policy_legislative,9090_State legislation of treatment for pregnant or parenting women that use substances,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,7_programs,policy_harm,9090_Treatment for pregnant women/mothers with addictions,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,7_programs,policy_legislative,9090_State legislation of treatment for pregnant or parenting women that use substances,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Steverson_2009,7_programs,policy_social,2_medical insurance changes,2_medical insurance changes,0,NA,NA,NA,NA,NA,NA,NA
Stoever_2002,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Stoever_2002,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Stover_2006,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Strickler_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Strickler_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,3_beneficial
Strike_2005,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Strike_2005,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Strike_2005,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Strike_2005,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,4_government policy,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Strike_2005,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,5_guidelines,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Strike_2005,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Strike_2005,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,1_increase
Stucke_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Suffoletto_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Suffoletto_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Sullivan_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Sullivan_2016,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Sun_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,2_legislations,policy_clinical,9090_hospital 'best practices' including introduction of EDIE system,9090_hospital 'best practices' including introduction of EDIE system,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,5_guidelines,policy_clinical,9090_hospital 'best practices' including introduction of EDIE system,9090_hospital 'best practices' including introduction of EDIE system,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,6_standards,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,6_standards,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,6_standards,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2017,6_standards,policy_clinical,9090_hospital 'best practices' including introduction of EDIE system,9090_hospital 'best practices' including introduction of EDIE system,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Sun_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Sung_2011,1_legal,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Sung_2018,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Surratt_2014,2_legislations,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Surratt_2014,3_regulation,policy_legislative,9090_pain clinic laws,9090_pain clinic laws,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Swartz_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Swartz_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Tadrous_2019,7_programs,policy_clinical,9090_patch for patch program,9090_patch for patch program,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Tadrous_2019,7_programs,policy_clinical,9090_patch for patch program,9090_patch for patch program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,0_no change
Tadrous_2019,7_programs,policy_clinical,9090_patch for patch program,9090_patch for patch program,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Tami_2014,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Tan_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Tan_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Tan_2018,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Tempalski_2008,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Tempalski_2008,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,0,NA,NA,NA,NA,NA,NA,NA
Tenney_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Tenney_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Tenney_2018,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Tesoriero_2009,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
The Network for Public Health Law_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
The Network for Public Health Law_2018,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Thomas_2013,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
Thongkhamcharoen_2012,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,2_legislations,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Thongkhamcharoen_2012,5_guidelines,policy_clinical,6_opioid prescribing standards - provider - pharmacist,6_opioid prescribing standards - provider - pharmacist,0,NA,NA,NA,NA,NA,NA,NA
Townsend_2019,7_programs,policy_harm,9090_naloxone distribution program,9090_naloxone_access_policies,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Townsend_2019,7_programs,policy_harm,9090_naloxone distribution program,9090_naloxone_access_policies,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,3_beneficial
Tran_2012,7_programs,policy_harm,9090_Methadone Maintenance Treatment,9090_Methadone Maintenance Treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,3_beneficial
Tran_2012,7_programs,policy_harm,9090_Methadone Maintenance Treatment,9090_Methadone Maintenance Treatment,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,4_detrimental
Tran_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Behavioral and health-related quality-of-life (HRQOL) outcomes,999,other 1,impact_other,9090_Behavioral and health-related quality-of-life (HRQOL) outcomes,3_beneficial
Tran_2016,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,9090_Behavioral and health-related quality-of-life (HRQOL) outcomes,999,other 1,impact_other,9090_Behavioral and health-related quality-of-life (HRQOL) outcomes,4_detrimental
Tran_2017,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Tran_2017,3_regulation,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Turner_2013,7_programs,policy_clinical,9090_opioid risk reduction initiative to increase urine testing,9090_opioid risk reduction initiative to increase urine testing,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Turner_2013,7_programs,policy_clinical,9090_opioid risk reduction initiative to increase urine testing,9090_opioid risk reduction initiative to increase urine testing,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,1_increase
Twillman_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,3_regulation,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,4_government policy,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Twillman_2016,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Tyndall_2002,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,0_no change
Unger_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
van Ameijden_2001,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
van Ameijden_2001,4_government policy,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
van Ameijden_2001,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
van Ameijden_2001,7_programs,policy_harm,1_needle exchange/availability,1_needle exchange/availability,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
van Ganse_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
van Ganse_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
van Ganse_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
van Ganse_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
van Ganse_2018,3_regulation,policy_prescription,3_withdraw drug,3_withdraw drug,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
vanBurskirk_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,0_no change
vanBurskirk_2017,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,2_decrease
vandewalker_2008,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
vandewalker_2008,1_legal,policy_criminal,9090_Termination of parental rights for pregnant women who use substances.,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
vandewalker_2008,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
vandewalker_2008,2_legislations,policy_criminal,9090_Termination of parental rights for pregnant women who use substances.,9090_pregnancy_related_drug_charges,0,NA,NA,NA,NA,NA,NA,NA
Varisco_2017,2_legislations,policy_prescription,1_drug rescheduling,1_drug rescheduling,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,1_increase
von Korff_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
von Korff_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
von Korff_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
von Korff_2016,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
von Korff_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
von Korff_2016,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
von Korff_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
von Korff_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,3_beneficial
von Korff_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
von Korff_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
von Korff_2019,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
von Korff_2019,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
von Korff_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
von Korff_2019,5_guidelines,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,2_decrease
vonaarburg_2004,3_regulation,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Vongchak_2005,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Vongchak_2005,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Vongchak_2005,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Vongchak_2005,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,1_increase
Vosburg_2017,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Vranken_2014,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Vranken_2016,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Vranken_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Vuong_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Vuong_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Vuong_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Vuong_2018,4_government policy,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Vuong_2018,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Vuong_2018,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Vuong_2018,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Vuong_2018,4_government policy,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Vuong_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,0_no change
Vuong_2018,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Vuong_2018,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Vyas_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Vyas_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Vyas_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Waal_2014,2_legislations,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,3_regulation,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_law_enforce,1_policing tactics,1_policing tactics,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_harm,3_SIS,3_SIS,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_social,1_welfare expansion/reform,1_welfare expansion/reform,0,NA,NA,NA,NA,NA,NA,NA
Waal_2014,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Wade_2017,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,0_no change
Wade_2017,3_regulation,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,0_no change
Wakeland_2013,7_programs,policy_clinical,9090_educational interventions,9090_educational interventions,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wakeland_2013,7_programs,policy_clinical,9090_educational interventions,9090_educational interventions,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Wakeland_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcomes_prescription,3_opioid availability,3,opioid availability,impact_oa,NA,2_decrease
Wakeland_2015,2_legislations,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Waldrop_2017,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Waldrop_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Waldrop_2017,5_guidelines,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Waldrop_2017,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Waldrop_2017,7_programs,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Waldrop_2017,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Walley_2013,7_programs,policy_harm,9090_overdose education and nasal naloxone distribution (OEND) program,9090_overdose education and nasal naloxone distribution (OEND) program,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Walley_2013,7_programs,policy_harm,9090_overdose education and nasal naloxone distribution (OEND) program,9090_overdose education and nasal naloxone distribution (OEND) program,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,0_no change
Walley_2013,7_programs,policy_harm,9090_overdose education and nasal naloxone distribution (OEND) program,9090_overdose education and nasal naloxone distribution (OEND) program,1,outcome_type,9090_2_visit to emergency department for opioids,999,other 1,impact_other,9090_2_visit to emergency department for opioids,0_no change
Wan_2016,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_2_Emergency Department presentations,998,other 2,impact_other_2,9090_2_Emergency Department presentations,0_no change
Wan_2016,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_arrests for use/ possession of heroin,999,other 1,impact_other,9090_arrests for use/ possession of heroin,1_increase
Wan_2016,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,9090_arrests for use/ possession of heroin,999,other 1,impact_other,9090_arrests for use/ possession of heroin,2_decrease
Wang_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wang_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Wang_2019,2_legislations,policy_clinical,9090_Health information technology,9090_Health information technology,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wang_2019,2_legislations,policy_clinical,9090_Health information technology,9090_Health information technology,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Wang_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wang_2019,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Wang_2019,7_programs,policy_clinical,9090_Health information technology,9090_Health information technology,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wang_2019,7_programs,policy_clinical,9090_Health information technology,9090_Health information technology,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,3_beneficial
Warren_2018,2_legislations,policy_criminal,1_drug courts,1_drug courts,0,NA,NA,NA,NA,NA,NA,NA
Warren_2018,2_legislations,policy_criminal,9090_early diversion,9090_early diversion,0,NA,NA,NA,NA,NA,NA,NA
Web_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Web_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,3_beneficial
Web_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,4_detrimental
Weber_2010,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,2_legislations,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,2_legislations,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,3_regulation,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,3_regulation,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,3_regulation,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,5_guidelines,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,5_guidelines,policy_clinical,2_availability of OAT - provider - doctors,2_availability of OAT - provider - doctors,0,NA,NA,NA,NA,NA,NA,NA
Weber_2010,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,0,NA,NA,NA,NA,NA,NA,NA
Wegman_2017,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Wegman_2017,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,4_detrimental
Wegman_2017,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Wegman_2017,7_programs,policy_clinical,7_compulsory treatment,7_compulsory treatment,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,4_detrimental
Weimer_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Weimer_2016,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Weiner_2017,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Weisberg_2016,1_legal,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,1_legal,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,1_legal,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,1_legal,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,2_legislations,policy_criminal,2_punitive charges,2_punitive charges,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,2_legislations,policy_legislative,2_illicit drug policies,2_illicit drug policies,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Weisberg_2016,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Wen_2013,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,3_beneficial
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,999_unclear
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,998_other 2,998,other 2,impact_other_2,NA,1_increase
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Wen_2015,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,999_other 1,999,other 1,impact_other,NA,1_increase
Wen_2017,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,1_access,1,access,impact_access,NA,1_increase
Wen_2017a,4_government policy,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Wen_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Wen_2018,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Wen_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Wen_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Wen_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Werb_2013,2_legislations,policy_clinical,9090_Prescription of heroine-assisted treatment (HAT),9090_prescription_heroin,0,NA,NA,NA,NA,NA,NA,NA
Westanmo_2015,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,2_decrease
Westanmo_2015,7_programs,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,2_opioid prescribing behaviours,2,opioid prescribing behaviours,impact_opb,NA,3_beneficial
Wettstein_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Whitelaw_2017,2_legislations,policy_legislative,3_decriminalization,3_decriminalization,0,NA,NA,NA,NA,NA,NA,NA
Whitmore_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,2_legislations,policy_theme,9090_educational campaigns targeting public and doctors,9090_educational campaigns targeting public and doctors,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,2_legislations,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,2_legislations,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,2_legislations,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,7_programs,policy_theme,9090_educational campaigns targeting public and doctors,9090_educational campaigns targeting public and doctors,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,7_programs,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,7_programs,policy_legislative,5_first responders,5_first responders,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,0,NA,NA,NA,NA,NA,NA,NA
Wickramatilake_2017,7_programs,policy_clinical,4_opioid prescribing standards,4_opioid prescribing standards,0,NA,NA,NA,NA,NA,NA,NA
Williams_2014,2_legislations,policy_clinical,7_compulsory treatment,7_compulsory treatment,0,NA,NA,NA,NA,NA,NA,NA
Wilson_2006,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Wilson_2006,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,999_unclear
Wilson_2018,7_programs,policy_criminal,9090_Diversion,9090_diversion,0,NA,NA,NA,NA,NA,NA,NA
Wilson_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Wilson_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Wilson_2019,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,999_unclear
Winstanley_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Wittouck_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,3_beneficial
Wittouck_2013,7_programs,policy_criminal,1_drug courts,1_drug courts,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,999_unclear
Wong_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Wong_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,1_increase
Wong_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,999_unclear
Wong_2019,2_legislations,policy_legislative,4_legalization,4_legalization,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,0_no change
Wood_2003,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_infectious,1_HIV,1,HIV,impact_hiv,NA,0_no change
Wood_2003,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,1_illegal drug availability,1,illegal drug availability,impact_non_pres_avail,NA,0_no change
Wood_2003,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,0_no change
Wood_2003,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Wood_2004,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_illegal,1_injection drug use,1,injection drug use,impact_idu,NA,0_no change
Wood_2004,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_non_pres,2_illegal drug use,2,illegal drug use,impact_non_pres_use,NA,0_no change
Wood_2004,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,2_oat,2,oat,impact_tfo,NA,0_no change
Wood_2004,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcome_type,999_other 1,999,other 1,impact_other,NA,0_no change
Wood_2004,8_strategies,policy_law_enforce,1_policing tactics,1_policing tactics,1,outcomes_treatment,999_other 1,999,other 1,impact_of,NA,4_detrimental
Wood_2004_2,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,2_decrease
Wood_2004_2,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
Wood_2006,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Wood_2006,7_programs,policy_harm,3_SIS,3_SIS,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Woodworth_2013,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Worrall_2009,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,0_no change
Worrall_2009,2_legislations,policy_criminal,1_drug courts,1_drug courts,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,1_increase
Wright_2017,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,0,NA,NA,NA,NA,NA,NA,NA
Xu_2018,2_legislations,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Xu_2018,4_government policy,policy_harm,9090_naloxone access laws,9090_naloxone_access_policies,1,outcomes_prescription,999_other 1,999,other 1,impact_pres_other,NA,1_increase
Yarbrough_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_pain management (in home health care setting),999,other 1,impact_other,9090_pain management (in home health care setting),3_beneficial
Yarbrough_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_pain management (in home health care setting),999,other 1,impact_other,9090_pain management (in home health care setting),4_detrimental
Yarbrough_2015,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcome_type,9090_pain management (in home health care setting),999,other 1,impact_other,9090_pain management (in home health care setting),999_unclear
Yarbrough_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,1_increase
Yarbrough_2018,2_legislations,policy_legislative,1_regulation of prescription drugs,1_regulation of prescription drugs,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Yenikomshian_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,4_overdose rates,4,overdose rates,impact_overdose,NA,2_decrease
Yenikomshian_2019,3_regulation,policy_prescription,2_changes in drug formulation,2_changes in drug formulation,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Young_2017,7_programs,policy_clinical,9090_Inform physicians if patient 4+ providers through letter,9090_Inform physicians if patient 4+ providers through letter,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,2_decrease
Young_2017,7_programs,policy_clinical,9090_Inform physicians if patient 4+ providers through letter,9090_Inform physicians if patient 4+ providers through letter,1,outcomes_prescription,5_opioid prescription fills,5,opioid prescription fills,impact_ou,NA,2_decrease
Zanis_2003,7_programs,policy_criminal,9090_Early prison release & entry into substance abuse and treatment facility,9090_Early prison release & entry into substance abuse and treatment facility,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,3_beneficial
Zarkin_2005,7_programs,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Zarkin_2005,7_programs,policy_criminal,9090_diversion,9090_diversion,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Zarkin_2011,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Zarkin_2011,7_programs,policy_clinical,1_availability of OAT,1_availability of OAT,1,outcome_type,8_health and  social services systems costs,8,health and  social services systems costs,impact_health,NA,2_decrease
Zarkin_2012,7_programs,policy_criminal,9090_Diversion,9090_diversion,1,outcome_type,5_criminal activity,5,criminal activity,impact_crim,NA,2_decrease
Zarkin_2012,7_programs,policy_criminal,9090_Diversion,9090_diversion,1,outcome_type,999_other 1,999,other 1,impact_other,NA,2_decrease
Zhu_2019,2_legislations,policy_social,2_medical insurance changes,2_medical insurance changes,1,outcomes_treatment,998_other 2,998,other 2,impact_of_2,NA,0_no change
Zolin_2019,5_guidelines,policy_clinical,5_opioid prescribing standards - provider - doctor,5_opioid prescribing standards - provider - doctor,1,outcomes_prescription,1_opioid prescribing rates,1,opioid prescribing rates,impact_opr,NA,0_no change
Zurhold_2003,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_type,999_other 1,999,other 1,impact_other,NA,3_beneficial
Zurhold_2003,2_legislations,policy_harm,3_SIS,3_SIS,1,outcome_illegal,999_other 1,999,other 1,impact_dui_2,NA,3_beneficial
